Seascape Capital Management Buys 174 Shares of Edwards Lifesciences Co. (NYSE:EW)

Seascape Capital Management boosted its position in Edwards Lifesciences Co. (NYSE:EW) by 0.5% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 32,989 shares of the medical research company’s stock after acquiring an additional 174 shares during the quarter. Seascape Capital Management’s holdings in Edwards Lifesciences were worth $2,177,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Equitable Trust Co. grew its position in Edwards Lifesciences by 379.7% in the 3rd quarter. Equitable Trust Co. now owns 65,888 shares of the medical research company’s stock valued at $4,348,000 after purchasing an additional 52,154 shares during the period. Leavell Investment Management Inc. lifted its stake in shares of Edwards Lifesciences by 3.3% in the third quarter. Leavell Investment Management Inc. now owns 9,923 shares of the medical research company’s stock valued at $655,000 after buying an additional 321 shares in the last quarter. Comprehensive Financial Consultants Institutional Inc. grew its holdings in shares of Edwards Lifesciences by 3.8% during the third quarter. Comprehensive Financial Consultants Institutional Inc. now owns 22,657 shares of the medical research company’s stock valued at $1,495,000 after buying an additional 824 shares during the last quarter. AIA Group Ltd increased its position in shares of Edwards Lifesciences by 91.7% during the third quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock worth $49,461,000 after acquiring an additional 358,556 shares in the last quarter. Finally, Presidio Capital Management LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $527,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 0.6 %

Shares of NYSE EW opened at $66.22 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The stock has a market capitalization of $39.89 billion, a PE ratio of 9.56, a P/E/G ratio of 3.74 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The business’s fifty day moving average price is $67.59 and its 200-day moving average price is $76.96.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 22.56%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.59 earnings per share. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Analyst Upgrades and Downgrades

EW has been the subject of a number of analyst reports. Morgan Stanley reiterated an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 11th. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Royal Bank of Canada lowered their price target on Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. The Goldman Sachs Group cut their price objective on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Finally, Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Seventeen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus target price of $75.67.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,250 shares of company stock valued at $2,746,988. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.